Medical Condition News

RSS

Study identifies specific chemical in smokeless tobacco products that induces oral cancer

The chemical (S)-N'-nitrosonornicotine, or (S)-NNN, which is present in smokeless tobacco products, is a strong oral carcinogen, according to results presented at the AACR Annual Meeting 2012, held here March 31 - April 4.

2 Apr 2012

Non-invasive brain stimulation cuts time to improve speech in stroke patients

One of the most frustrating challenges for some stroke patients can be the inability to find and speak words even if they know what they want to say. Speech therapy is laborious and can take months. New research is seeking to cut that time significantly, with the help of non-invasive brain stimulation.

2 Apr 2012

Successful aneurysm treatment may not improve quality of life

Patients with unruptured brain aneurysms have significant reductions in several areas of quality of life—especially physical functioning, reports a study in the April issue of Neurosurgery, official journal of the Congress of Neurological Surgeons. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

2 Apr 2012

CYP1B1 protein may be a potential target for intervention in head and neck cancer

Squamous cell carcinoma of the head and neck-which typically arises from thin, flat cells that line moist surfaces inside the mouth, nose and throat-is the sixth most common type of cancer worldwide, and it has a relatively low five-year survival rate and a high recurrence rate.

2 Apr 2012

PolyTherics, Spirogen enter research collaboration to produce novel ADCs for treatment of cancer

PolyTherics Limited, a provider of solutions to enable the development of better biopharmaceuticals, and Spirogen Limited, a leading oncology-focused company developing DNA sequence-targeted agents, announce that they have formed a research collaboration to develop antibody drug conjugates that combine PolyTherics' proprietary site-specific conjugation chemistry with Spirogen's highly potent novel cytotoxic drugs to produce novel ADCs for the treatment of cancer.

2 Apr 2012

Special fatty molecules pave novel way to treat infections, autoimmune diseases, allergies and cancer

An international research team led by scientists from Singapore Immunology Network (SIgN) under the Agency of Science, Technology and Research (A*STAR) discovered that a special class of fatty molecules is essential for activating a unique group of early-responding immune cells.

2 Apr 2012

Safe method for destroying cancer cells using death cap mushroom poison

The mere thought of an identification error sends a chill down the spine of any mushroom lover: The death cap mushroom (Amanita phalloides), which resembles the common white button mushroom, contains one of the most deadly poisons found in nature, α-amanitin.

2 Apr 2012

New technology prevents stone migration during procedures to retrieve urinary stones

Boston Scientific Corporation announces the launch of its BackStop Gel, a new technology designed to prevent stone migration during procedures used to break up and retrieve urinary stones.

2 Apr 2012

Eisai, University of Kansas grant water-soluble pro-drug technology patent to OneWorld Health

OneWorld Health (OWH), a nonprofit that develops lifesaving medicines for neglected diseases, announced that it has signed a nonexclusive patent agreement with Eisai Co., Ltd., for a water-soluble pro-drug technology patent. OWH will use the pro-drug technology to advance development of iOWH032, its new drug to treat acute secretory diarrhea.

2 Apr 2012

Sleep enhances emotionally positive memories

Sleep plays a powerful role in preserving our memories. But while recent research shows that wakefulness may cloud memories of negative or traumatic events, a new study has found that wakefulness also degrades positive memories. Sleep, it seems, protects positive memories just as it does negative ones, and that has important implications for the treatment of post-traumatic stress disorder.

2 Apr 2012

Targeting inflammatory pathways may lead to new therapies

Scientists at Fox Chase Cancer Center have uncovered more details about how defects in components of the machinery that makes new proteins can lead to blood and other cancers.

2 Apr 2012

TYRX enrolls 1000th patient in CITADEL/CENTURION AIGISRx Antibacterial Envelope studies

TYRX, Inc., the leader in the commercialization of implantable medical devices designed to help reduce surgical-site infections (SSIs) associated with cardiovascular implantable electronic devices (CIEDs), announced today that the 1000th patient has been enrolled into the CITADEL & CENTURION clinical studies evaluating the company's AIGISRx Antibacterial Envelope.

2 Apr 2012

ulrich medical releases enhancements to spinal implant portfolio

ulrich medical USA, Inc. today announced the release of two important product line enhancements to their growing spinal implant portfolio of expandable cage technologies.

2 Apr 2012

Nektar commences dosing in NKTR-192 Phase 1 clinical study for treatment of acute pain

Nektar Therapeutics announced today that the first subjects were dosed last week in a Phase 1 clinical study to evaluate the pharmacokinetics and safety of NKTR-192, the company's novel short-acting mu-opioid analgesic candidate.

2 Apr 2012

Enrollment complete in Oncolytics REOLYSIN combination trial for head and neck cancers

Oncolytics Biotech Inc. announced today that it has completed enrollment in the first, 80 patient stage of its Phase III clinical trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers (REO 018).

2 Apr 2012

$Aeterna Zentaris X-PECT Phase 3 refractory advanced colorectal cancer trial fails to meet primary endpoint$

Aeterna Zentaris X-PECT Phase 3 refractory advanced colorectal cancer trial fails to meet primary endpoint

Aeterna Zentaris Inc. today announced that the Phase 3 "X-PECT" (Xeloda + Perifosine Evaluation in Colorectal cancer Treatment) clinical trial evaluating perifosine + capecitabine (Xeloda) in patients with refractory advanced colorectal cancer did not meet the primary endpoint of improving overall survival versus capecitabine + placebo.

2 Apr 2012

Blocking PRC2 protein may help protect against AML

Scientists at Cold Spring Harbor Laboratory have identified a candidate drug target for treating acute myeloid leukemia, a white blood cell cancer that proliferates out of control in the bone marrow.

2 Apr 2012

Clinical data for cabozantinib to be presented at ASCO annual meeting

Exelixis, Inc. announced today that its lead compound, cabozantinib, will be the subject of nine separate data presentations at the upcoming Annual Meeting of the American Society of Clinical Oncology.

2 Apr 2012

AngioDynamics presents NanoKnife System clinical study results at SSO 2012

AngioDynamics, a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced presentations on NanoKnife System clinical experience were given at the Society of Surgical Oncology (SSO) 2012 conference that took place March 21-24, 2012, in Orlando, Fla.

2 Apr 2012

Phage therapy can combat Pseudomonas infections in CF patients

Scientists in Cork have identified a novel therapy for the bacteria which cause infections in cystic fibrosis patients.

2 Apr 2012

Medical Condition News

Study identifies specific chemical in smokeless tobacco products that induces oral cancer

Non-invasive brain stimulation cuts time to improve speech in stroke patients

Successful aneurysm treatment may not improve quality of life

CYP1B1 protein may be a potential target for intervention in head and neck cancer

PolyTherics, Spirogen enter research collaboration to produce novel ADCs for treatment of cancer

Special fatty molecules pave novel way to treat infections, autoimmune diseases, allergies and cancer

Safe method for destroying cancer cells using death cap mushroom poison

New technology prevents stone migration during procedures to retrieve urinary stones

Eisai, University of Kansas grant water-soluble pro-drug technology patent to OneWorld Health

Sleep enhances emotionally positive memories

Targeting inflammatory pathways may lead to new therapies

TYRX enrolls 1000th patient in CITADEL/CENTURION AIGISRx Antibacterial Envelope studies

ulrich medical releases enhancements to spinal implant portfolio

Nektar commences dosing in NKTR-192 Phase 1 clinical study for treatment of acute pain

Enrollment complete in Oncolytics REOLYSIN combination trial for head and neck cancers

Aeterna Zentaris X-PECT Phase 3 refractory advanced colorectal cancer trial fails to meet primary endpoint

Blocking PRC2 protein may help protect against AML

Clinical data for cabozantinib to be presented at ASCO annual meeting

AngioDynamics presents NanoKnife System clinical study results at SSO 2012

Phage therapy can combat Pseudomonas infections in CF patients

In the Thymus We Trust: ProTcell Therapy & the Future of Allogeneic Immunotherapy

Making Complex Cell Culture Easy and Efficient with AI

This International Women’s Day, Meet the Scientist Changing Women’s Healthcare

Latest News